Name

Masarykův Onkologický Ústav

Legal name

Masarykův Onkologický Ústav

Website

https://mou.cz

Company type

Private

Founded year

1935

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Oncology Healthcare Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Medical and Diagnostic Laboratories (62151), General Medical and Surgical Hospitals (622110)

SIC

Services-Hospitals (8060), Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• Oncology care
• Cancer treatment
• Clinical trials
• Cancer research
• Biobank services

Headquarters

HQ city

Brno

HQ country

Czechia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Healthcare Services Revenue: Public healthcare institution funded primarily through Czech public health insurance (Všeobecná zdravotní pojišťovna and other insurance companies). Services provided to insured patients, foreign nationals with EU healthcare cards, and self-paying patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Masarykův Onkologický Ústav (Masaryk Memorial Cancer Institute) is a comprehensive oncology center providing integrated cancer care for adult patients with solid tumors, including diagnostics, chemotherapy, radiotherapy, surgical treatments (including robotic surgery), and long-term follow-up. It operates 22 specialized diagnostic and treatment centers, the Cancer Prevention Center (COP), and the RECAMO molecular oncology research center with an associated biobank integrated with the BBMRI-ERIC pan-European network.

Product overview

Masarykův Onkologický Ústav (MOÚ) is a comprehensive cancer center providing integrated oncological care for adult patients with solid tumors. The institution operates 22 specialized diagnostic and treatment centers, combining all necessary medical disciplines in one facility. Key offerings include the Centrum onkologické prevence (Cancer Prevention Center) for screening and prevention, comprehensive treatment services, and an extensive research division comprising RECAMO (molecular oncology research) and the Banka biologického materiálu (Biobank). The institute also provides patient support services including information/education centers, psychological care, nutritional services, and spiritual care. Research activities are supported by clinical trials programs, the Early Phase Trial Unit, and academic publications including the Časopis Klinická onkologie. MOÚ serves as one of two National Oncology Centers in the Czech Republic.

Differentiator

Problem solved

Functional benefit

Brands

• RECAMO: Research Center for Applied Molecular Oncology - focuses on cancer biology research
• BBMRI.cz
• Centrum onkologické prevence (COP)

Products and services

• Comprehensive Cancer Treatment (MOÚ/MMCI) Comprehensive oncology care for adult patients with solid tumors, combining diagnostics, chemotherapy, radiotherapy, and surgery under one roof.
• Cancer Prevention Center (Centrum onkologické prevence / COP) Cancer prevention programs offering screening, risk assessment, and early detection services, including risk calculators and preventive examinations.
• Diagnostic and Treatment Centers (22 centers) Twenty-two specialized diagnostic and treatment centers providing focused multidisciplinary care for specific cancer types.
• Robotic Surgery Service Performs 300 robotic surgical procedures annually as part of the institute's 5,000 total surgeries per year.
• Advanced Radiotherapy Service Modern radiotherapy treatment for more than 5,000 patients annually, including children, delivered across the institute's facilities.
• Bank of Biological Material (Biobank) Long-term frozen tissue and biological material storage for oncology research, integrated with BBMRI.cz national and BBMRI-ERIC pan-European biobank networks.
• RECAMO Research Center Research Center for Applied Molecular Oncology with six working groups conducting long-term research in cancer biology, proteomics, genomics, and biomarker discovery.
• Clinical Trials Program Participation in nearly 100 active European and global clinical trials testing new drugs and chemoradiotherapy combinations.
• Early Phase Trial Unit Dedicated unit conducting early-phase clinical trials for new drugs and treatment combinations.
• Consultation Outpatient Clinic for Foreign Patients and Self-Payers Dedicated outpatient clinic for international patients and self-payers to arrange oncology appointments and coordinate care, with established fee schedules.
• Second Opinion Service (Druhý názor) Multi-disciplinary indication boards comprising top experts providing second opinion consultations for complex oncology cases.
• MOÚ Mobile Application Mobile application for patients to access institute services and information.
• Information and Education Centre (IEC) Centre producing and disseminating patient and public educational materials and campaigns, with patient counseling and resource access.

Quantifiable outcome

• Early detection of cancer increases treatment success by up to 100%

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Swiss Biobanking Platform (CS-BIQ Project)coreStrategic or Co-development Partner · 1 January 2026Czech-Swiss cooperation connecting BBMRI.cz and BBMRI.ch to strengthen biobanking quality and interoperability. Budget: 26,965,000 CZK. Focuses on quality harmonization and FAIR data principles.
• BBMRInv Project PartnerscoreStrategic or Co-development Partner · 1 April 2024Development and Modernisation of the National Biobank Network project with partners: Charles University, Palacký University Olomouc, Institute of Rheumatology, Masaryk University, Institute of Hematology and Blood Transfusion. Budget: 184,510,030 CZK
• BBMRI.cz (Czech National Node of Biobanks)coreStrategic or Co-development PartnerMMCI participates in and coordinates the Czech National Node of Biobanks within the pan-European network BBMRI-ERIC (Biobanking and Biomolecular Resources Research Infrastructure). Contributed to developing online tools including Negotiator, Federated Search, Directory, and Locator for sample harmonization and data integration.
• EURACAN (European Reference Network)coreStrategic or Co-development PartnerEuropean Reference Network for rare adult solid cancers, connecting specialized healthcare providers across Europe to ensure optimal care for patients with rare cancers.
• OECI (Organization of European Cancer Institutes)coreStrategic or Co-development PartnerEuropean organization setting quality standards for cancer care and research. MMCI holds OECI certification as the only facility in Czech Republic meeting these standards.
• CZECRINminorStrategic or Co-development PartnerCzech Clinical Research Infrastructure Network supporting clinical trials and research collaboration.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Institut Curie: Paris-based cancer hospital and research center combining treatment with translational oncology research. The European benchmark for integrating a dedicated cancer hospital with a research center, paralleling MMCI's RECAMO + clinical model.
• The Royal Marsden NHS Foundation Trust: UK's dedicated cancer hospital with research arm (Institute of Cancer Research). Comparable as a specialty oncology hospital with deep clinical trial activity and reputation heritage — similar institutional model to MMCI.
• Charité Comprehensive Cancer Center: Berlin-based comprehensive cancer center integrated into Charité university hospital. Closely comparable as a publicly-funded European cancer center with strong research programs and clinical trial infrastructure in the same Central European ecosystem as MMCI.
• Netherlands Cancer Institute (NKI): Specialized oncology hospital and research institute in Amsterdam combining treatment and basic/translational research. Comparable scale and model, including dedicated research divisions and clinical trial activity akin to RECAMO.
• Gustave Roussy Institute: Leading European comprehensive cancer center located in Villejuif, France. The closest geographic and functional peer — a publicly-funded specialty cancer hospital with strong translational research, clinical trials, and European reference network participation similar to MMCI.

Broad incumbents

• National Cancer Institute (NCI): U.S. government agency for cancer research and oversight. Comparable as a publicly-funded entity coordinating cancer research, standards, and clinical trial networks — analogous to MMCI's national reference and coordination role in the Czech Republic.
• MD Anderson Cancer Center: One of the world's leading comprehensive cancer centers based in Houston, Texas. Directly comparable as a specialty oncology hospital/research institute combining diagnostics, surgery, radiotherapy, chemotherapy, and clinical trials under a single brand.
• Memorial Sloan Kettering Cancer Center: Preeminent U.S. specialty cancer hospital and research institute with deep clinical trials and translational research programs. Closely mirrors MMCI's model of integrating treatment, research, biobanking, and education in a single dedicated oncology institution.

Regional players

• Institute of Oncology Ljubljana: Slovenia's national cancer center, the most directly comparable Central European institution. Similar public-hospital model and scale providing comprehensive oncology services including research and clinical trials.

Others

• The Christie NHS Foundation Trust:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCvZw3zIoiQZXHUmqvXNi-vw
• Facebookfacebook.com/MOU.Brno
• LinkedInlinkedin.com/company/mou-brno
• Instagraminstagram.com/mou.brno/?hl=cs
• Xx.com/MOU_Brno

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Masarykův Onkologický Ústav